The Globe News
LONDON. – The results of AstraZeneca in 2020 they soared in such a way that the British pharmaceutical company obtained a net profit of 3.144 million dollars (2.592 million euros), 159% more than the previous year, as reported by the company this Thursday to the London Stock Exchange.
This accolade occurs as a result of the sales of its vaccine against Covid-19, designed jointly with the University of Oxford, and which have allowed it to reach total revenues that reached 2020 million dollars (26.617 million euros) in 21.945. ), which represents an increase of 9,1% compared to those registered in 2019.
In addition to the launch of new drugs related to the coronavirus, those dedicated to other pathologies such as asthma have also served to boost sales balances. The successful results, says the pharmacist, have occurred despite the drop in the distribution of medicines for cancer treatments, which were postponed to give priority to those dedicated to the fight against the virus.
The pharmaceutical group also registered an increase in its expenses, in particular those related to logistics. "The successes of our drugs in development, the acceleration of our company's performance and the advancement of the covid-19 vaccine show what we can achieve," said Pascal Soriot, CEO of the firm. Source The Country
Photo external source